<DOC>
	<DOCNO>NCT02285361</DOCNO>
	<brief_summary>To monitor safety profile efficacy GIOTRIF® ( afatinib dimaleate , q.d ) Korean patient locally advanced metastatic non-small cell lung cancer ( NSCLC )</brief_summary>
	<brief_title>GIOTRIF rPMS Korean Patients With NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients start GIOTRIF® accordance approve label Korea 2 . Age = 19 year enrolment 3 . Patients sign data release consent form Exclusion criterion : 1 . Known hypersensitivity afatinib excipients 2 . Patients rare hereditary condition galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption 3 . Patients GIOTRIF® contraindicate accord local label</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>110 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>